Study is the first to use protein interaction networks to study whether existing drugs could treat autism, finding potential in a common antidiarrheal drug. There are currently no effective treatments for the core symptoms of autism spectrum disorder (ASD), such as difficulties with socializing a
Researchers searched existing drugs, looking for potential treatments for the core symptoms of autism spectrum disorder. The most promising one they found is called loperamide, better known by the brand name Imodium, which is commonly used for diarrhea.
Can you teach an old drug new tricks? Drug treatments for the core symptoms of autism spectrum disorder are not currently available. However, could an existing drug provide a new treatment, even if it previously had no association with ASD? This was the question asked by a new study that was published on September 12 in the journal. The researchers used a computer model that encompasses proteins involved in ASD and the way they interact.
Loperamide is a medicine to treat short-term diarrhea or irritable bowel syndrome . It is more commonly known by the brand name Imodium, and is available over-the-counter . It is on the World Health Organization’s List of Essential Medicines. The most promising drug is called loperamide, which is commonly used for diarrhea. Although it might seem strange that an anti-diarrheal drug could treat core ASD symptoms, the scientists have developed a hypothesis about how it may work.Loperamide binds to and activates a protein called the μ-opioid receptor, which is normally affected by opioid drugs, such as morphine.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Texas is one of the worst states in the country for workers, study findsOxfam America, a nonprofit organization working to end poverty, tracked how states and territories protect, support and pay workers.
Les mer »
Pennsylvania city among top 15 best for Gen Z: studyA city in Pennsylvania was ranked among the top 15 best for Gen Z.
Les mer »
New study highlights ketamine's promise for treatment-resistant depressionTreatment centers using the drug to treat severe depression still remain highly unregulated.
Les mer »
Two-thirds of young adults have ‘work-from-home back’: studyA new poll conducted on behalf of campaign group Mind Your Back has discovered a new phenomenon among young adults — WFH back.
Les mer »
Pfizer begins late-stage human study on an mRNA flu shotDrugmaker Pfizer said Wednesday it has begun a late-stage human trial of an influenza vaccine that uses the pioneering messenger-RNA deployed widely for the coronavirus.
Les mer »